Oteseconazole, an investigational oral antifungal therapy, was shown to be safe and effective in the treatment of acute and recurrent vulvovaginal candidiasis, according to a study presented ...

Oteseconazole was noninferior to fluconazole in the proportion of subjects with resolved acute VVC infections at day 14 — 93.2% for the oteseconazole group vs 95.8% for the fluconazole/placebo ...

Topline results were announced from two phase 3 trials evaluating oteseconazole (VT-1161; Mycovia Pharmaceuticals) for the treatment of recurrent vulvovaginal candidiasis (VVC).

VIVJOA™ (oteseconazole), the first FDA-approved product for Mycovia, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a ...

Mycovia Pharmaceuticals, Inc. ("Mycovia") has announced enrollment of the first participant in an investigator-initiated clinical trial evaluating oteseconazole and other investigational products ...

Mycovia Pharmaceuticals announces US FDA acceptance and Priority Review of New Drug Application for oteseconazole for the treatment of recurrent vulvovaginal candidiasis. News release. Mycovia ...

Compared with the placebo group, the oteseconazole group had a significantly lower incidence rate of acute VVC between 48 and 96 weeks (21% vs. 5%; P = .007) and from randomization through week 96 ...

DURHAM – Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for oteseconazole, an oral antifungal product for the ...

The US Food and Drug Administration (FDA) has approved oteseconazole capsules (Vivjoa), an azole antifungal agent for the prevention of recurrent yeast infections in females who are not of ...

Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) ...